1921
Volume 94, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract

Leishmaniasis, a neglected vector-borne disease caused by the protozoan parasite , is encountered in 98 countries causing serious concerns to public health. The most alarming is the development of parasite drug resistance, a phenomenon increasingly encountered in the field rendering chemotherapy ineffective. Although resistance to drugs is a complex phenomenon, the rate of efflux of the fluorescent dye Rhodamine-123 from the parasite body, using flow cytometry, is an indication of the isolate's ability to efflux the drug, thus avoiding death. The rate of efflux measured 275 strains, isolated from patients and dogs from Greece and Cyprus, was measured and mapped to study the geographical distribution of the multidrug resistance (MDR) gene expression as an indication of the drug resistance of the parasite. The map showed that out of the seven prefectures, where dogs presented high efflux rates, five also had patients with high efflux rates. In one, out of the 59 prefectures studied, the highest number of isolates with efflux slope α > 1, in both human and dog isolates, was found; a fact which may suggest that spread of drug resistance is taking place. The virulence of the strains, assessed after infecting human macrophages of the THP-1 cell line, fluctuated from 1% to 59.3% with only 2.5% of the isolates showing infectivity > 50%. The most virulent strains were isolated from Attica and Crete.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.15-0658
2016-05-04
2017-11-23
Loading full text...

Full text loading...

/deliver/fulltext/14761645/94/5/987.html?itemId=/content/journals/10.4269/ajtmh.15-0658&mimeType=html&fmt=ahah

References

  1. Ntais P, Sifaki-Pistola D, Christodoulou V, Messaritakis I, Pratlong F, Poupalos G, Antoniou M, , 2013. Leishmaniases in Greece. Am J Trop Med Hyg 89: 906915.[Crossref]
  2. Christodoulou V, Antoniou M, Ntais P, Messaritakis I, Ivović V, Dedet JP, Pratlong F, Dvorak V, Tselentis Y, , 2012. Re-emergence of visceral and cutaneous leishmaniasis in the Greek Island of Crete. Vector Borne Zoonotic Dis 12: 214222.[Crossref]
  3. Antoniou M, Messaritakis I, Christodoulou V, Ascoksilaki I, Kanavakis N, Sutton A, Carson C, Courtenay O, , 2009. Increasing incidence of zoonotic visceral leishmaniasis due to Leishmania infantum on the Greek island of Crete. Emerg Infect Dis 15: 932934.[Crossref]
  4. Ntais P, Christodoulou V, Tsirigotakis N, Dokianakis E, Dedet JE, Pratlong F, Antoniou M, , 2014. Will the introduction of Leishmania tropica MON-58, in the island of Crete, lead to the settlement and spread of this rare zymodeme? Acta Trop 132: 125130.[Crossref]
  5. Mazeris A, Soteriadou K, Dedet JP, Haralambous C, Tsatsaris A, Moschandreas J, Messaritakis I, Christodoulou V, Papadopoulos B, Ivovic V, Pratlong F, Loucaides F, Antoniou M, , 2010. Leishmaniases and the Cyprus paradox. Am J Trop Med Hyg 82: 441448.[Crossref]
  6. Antoniou M, Haralambous C, Mazeris A, Pratlong F, Dedet JP, Soteriadou K, , 2008. Leishmania donovani leishmaniasis in Cyprus. Lancet Infect Dis 8: 67.[Crossref]
  7. Antoniou M, Haralambous C, Mazeris A, Pratlong F, Dedet JP, Soteriadou K, , 2009. Leishmania donovani leishmaniasis in Cyprus. Lancet Infect Dis 9: 7677.[Crossref]
  8. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M, , 2012. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 7: e35671.[Crossref]
  9. Maroli M, Rossi L, Baldelli R, Capelli G, Ferroglio E, Genchi C, Gramiccia M, Mortarino M, Pietrobelli M, Gradoni L, , 2008. The northward spread of leishmaniasis in Italy: evidence from retrospective and ongoing studies on the canine reservoir and phlebotomine vectors. Trop Med Int Health 13: 256264.[Crossref]
  10. Bogdan C, Schönian G, Bañuls AL, Hide M, Pratlong F, Lorenz E, Röllinghoff M, Mertens R, , 2001. Visceral leishmaniasis in a German child who had never entered a known endemic area: case report and review of the literature. Clin Infect Dis 32: 302306.[Crossref]
  11. Tánczos B, Balogh N, Király L, Biksi I, Szeredi L, Gyurkovsky M, Scalone A, Fiorentino E, Gramiccia M, Farkas R, , 2012. First record of autochthonous canine leishmaniasis in Hungary. Vector Borne Zoonotic Dis 12: 588594.[Crossref]
  12. Yah CS, Fatumo S, , 2010. In-silico studies of multi drug resistance (MDR) genetic markers of Plasmodium species. J Comput Biol Bioinform Res 2: 005009.
  13. Delgadillo DM, Perez DG, Gomez C, Ponce A, Paz F, Bañuelos C, Mendoza L, López C, Orozco E, , 2002. The Entamoeba histolytica EhPgp5 (MDR-like) protein induces swelling of the trophozoites and alters chloride-dependent currents in Xenopus laevis oocytes. Microb Drug Resist 8: 1526.[Crossref]
  14. Riordan JR, Deuchars K, Kartner N, Alon N, Trent J, Ling V, , 1985. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 316: 817819.[Crossref]
  15. Rai S, Bhaskar Goel SK, Nath Dwivedi U, Sundar S, Goyal N, , 2013. Role of efflux pumps and intracellular thiols in natural antimony resistant isolates of Leishmania donovani . PLoS ONE 8: e74862.[Crossref]
  16. Mookerjee Basu J, Mookerjee A, Banerjee R, Saha M, Singh S, Naskar K, Tripathy G, Sinha PK, Pandey K, Sundar S, Bimal S, Das PK, Choudhuri SK, Roy S, , 2008. Inhibition of ABC transporters abolishes antimony resistance in Leishmania infection. Antimicrob Agents Chemother 52: 10801093.[Crossref]
  17. Coelho AC, Messier N, Ouellette M, Cotrim PC, , 2007. Role of the ABC transporter PRP1 (ABCC7) in pentamidine resistance in Leishmania amastigotes. Antimicrob Agents Chemother 51: 30303032.[Crossref]
  18. Messaritakis I, Christodoulou V, Mazeris A, Koutala E, Vlahou A, Papadogiorgaki S, Antoniou M, , 2013. Drug resistance in natural isolates of Leishmania donovani s.l. promastigotes is dependent of Pgp170 expression. PLoS One 8: e65467.[Crossref]
  19. Croft SL, Sundar S, Fairlamb AH, , 2006. Drug resistance in leishmaniasis. Clin Microbiol Rev 19: 111126.[Crossref]
  20. Thakur CP, Kumar M, Pandey AK, , 1991. Comparison of regimes of treatment of antimony-resistant kala-azar patients: a randomized study. Am J Trop Med Hyg 45: 435441.
  21. Jha TK, Olliaro P, Thakur CP, Kanyok TP, Singhania BL, Singh IJ, Singh NK, Akhoury S, Jha S, , 1998. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ 316: 12001205.[Crossref]
  22. Higgins CF, , 1992. ABC transporters: from microorganisms to man. Annu Rev Cell Biol 8: 67113.[Crossref]
  23. Hughes AL, , 1994. Evolution of the ATP-binding-cassette transmembrane transporters of vertebrates. Mol Biol Evol 11: 899910.
  24. Ling V, , 1997. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 40: S3S8.[Crossref]
  25. Howard MK, Pharoah MM, Ashall F, Miles MA, , 1991. Human urine stimulates growth of Leishmania in vitro. Trans R Soc Trop Med Hyg 85: 477479.[Crossref]
  26. World Health Organization, 1991. Basic Laboratory Methods in Medical Parasitology. Geneva, Switzerland: WHO.
  27. Ferroglio E, Trisciuoglio A, Gastaldo S, Mignone W, Delle Piane M, , 2002. Comparison of ELISA, IFAT, and Western blot for the serological diagnosis of Leishmania infantum infection in dog. Parassitologia 44 (Suppl 1) 64.
  28. Lightner LK, Chulay JD, Bryceson AD, , 1983. Comparison of microscopy and culture in the detection of Leishmania donovani from splenic aspirates. Am J Trop Med Hyg 32: 296299.
  29. Lemesre JL, Darcy F, Kweider M, Capron A, Santoro F, , 1988. Requirements of defined cultivation conditions for standard growth of Leishmania promastigotes in vitro. Acta Trop 45: 99108.
  30. Warren S, , 1997. Current Protocols in Immunology. Hoboken, NJ: John Wiley & Sons, Inc., A.3B.1A.3B.2.
  31. Kanellopoulos P, Dokianakis E, Tsirigotakis N, Koutala E, Antoniou M, , 2014. Assessment of the infectivity potential of Leishmania infantum, using flow cytometry. Exp Parasitol 145: 2933.[Crossref]
  32. Mehta CR, Patel NR, , 1996. SPSS Exact Test 7.0 for Windows. Chicago, IL: Marketing Department, SPSS Inc.
  33. Marques de Sá JP, , 2007. Applied Statistics Using SPSS, STATISTICA, MATLAB and R, 2nd edition, Chapters 2 and 5. New York, NY: Springer Verlag.[Crossref]
  34. Griffith A, , 2010. SPSS For Dummies, 2nd edition. Indianapolis, IN: Wiley Publishing, Inc.
  35. Koliou MG, Soteriades ES, Ephros M, Mazeris A, Antoniou M, Elia A, Novelli V, , 2008. Hemophagocytic lymphohistiocytosis associated with Epstein Barr virus and Leishmania donovani coinfection in a child from Cyprus. J Pediatr Hematol Oncol 30: 704707.[Crossref]
  36. Katakura K, Chang KP, , 1989. H DNA amplification in Leishmania resistant to both arsenite and methotrexate. Mol Biochem Parasitol 34: 189191.[Crossref]
  37. Ouellette M, Fase-Fowler F, Borst P, , 1990. The amplified H circle of methotrexate-resistant Leishmania tarentolae contains a novel P-glycoprotein gene. EMBO J 9: 10271033.
  38. Ouellette M, Hettema E, Wust D, Fase-Fowler F, Borst P, , 1991. Direct and inverted DNA repeats associated with P-glycoprotein gene amplification in drug resistant Leishmania . EMBO J 10: 10091016.
  39. Henderson DM, Sifri CD, Rodgers M, Wirth DF, Hendrickson N, Ullman B, , 1992. Multidrug resistance in Leishmania donovani is conferred by amplification of a gene homologous to the mammalian MDR1 gene. Mol Cell Biol 12: 28552865.[Crossref]
  40. Hendrickson N, Sifri CD, Henderson DM, Allen T, Wirth DF, Ullman B, , 1993. Molecular characterization of the ldmdr1 multidrug resistance gene from Leishmania donovani . Mol Biochem Parasitol 60: 5364.[Crossref]
  41. Blast website. Available at: http://blast.ncbi.nlm.nih.gov/Blast.cgi. Accessed April 15, 2013.
  42. Mandal G, Sarkar A, Saha P, Singh N, Sundar S, Chatterjee M, , 2009. Functionality of drug efflux pumps in antimonial resistant Leishmania donovani field isolates. Indian J Biochem Biophys 46: 8692.
  43. Gourbal B, Sonuc N, Bhattacharjee H, Legare D, Sundar S, Ouellette M, Rosen BP, Mukhopadhyay R, , 2004. Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. J Biol Chem 279: 3101031017.[Crossref]
  44. Messaritakis I, Mazeris A, Koutala E, Antoniou M, , 2010. Leishmania donovani s.l.: evaluation of the proliferation potential of promastigotes using CFSE staining and flow cytometry. Exp Parasitol 125: 384388.[Crossref]
  45. Antoniou M, Doulgerakis C, Pratlong F, Dedet JP, Tselentis Y, , 2004. Short report: treatment failure due to mixed infection by different strains of the parasite Leishmania infantum . Am J Trop Med Hyg 71: 7172.
  46. Seblova V, Oury B, Eddaikra N, Aït-Oudhia K, Pratlong F, Gazanion E, Maia C, Volf P, Sereno D, , 2014. Transmission potential of antimony-resistant Leishmania field isolates. Antimicrob Agents Chemother 58: 62736276.[Crossref]
  47. Mary C, Faraut F, Deniau M, Dereure J, Aoun K, Ranque S, Piarroux R, , 2010. Frequency of drug resistance gene amplification in clinical leishmania strains. Int J Microbiol 2010: pii: 819060.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.15-0658
Loading
/content/journals/10.4269/ajtmh.15-0658
Loading

Data & Media loading...

  • Received : 10 Sep 2015
  • Accepted : 05 Jan 2016

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error